According to a filing with SEDI, Profound Medical (NASDAQ:PROF; TSX:PRN) president, Richard Fabian, acquired a total of 10,000 shares of Profound on the open market today at a cost of $59,800 (U.S.).
In a sign of confidence, the transaction came closely on the heels of Mr. Fabian’s appointment on September 1st.
In the press release announcing his appointment, Mr. Fabian stated, “I am incredibly energized to join Profound at such a transformative time in the evolutions of both robotic and incisionless surgeries. By combining the unrivalled precision and patient-centered customization enabled by real-time MRI guidance and thermometry, artificial intelligence, and supervised autonomous robotics, Profound is truly changing the paradigm for patients facing prostate disease and other conditions – proving that effective treatment no longer requires compromising a patient’s quality of life. I am honored to be part of a team that is actively replacing uncertainty with clarity and expanding the boundaries of modern medicine.”
